Newsletter Volume 38, Number 3, 2023

Introduction

　Summer is finally here, and we are at the turn of the year. In May, the new coronavirus infection that has transformed our lives was reclassified as a category 5 infectious disease, the same category as seasonal influenza. It can be said that the dynamics of the virulent new coronavirus has entered a new steady state in which it coexists with humans, just as it has done in the past. Some of you may be making plans for your summer vacation this year, hoping that the virus coronas will be back this year.

　By the way, there has been a lot of talk recently about the “decline in quality”. The quality of research, faculty, students, new employees, and even the quality of the muscles of people today vary. Why is it that quality is so often called into question in the midst of the digitalization of society and the development of science and technology? Perhaps it is a phenomenon that indicates the inflection point at which modern man is being overtaken by the technology he has created. On the other hand, although vague, such rapid changes in the environment may also trigger the evolution of modern man. I hope to contribute to the thinning of pharmacokinetics, which I love, by staying alert to changes while protecting what is important to me.

　When I attended a conference, I was asked, “What kind of science is pharmacokinetics? I was once asked, “What kind of science is pharmacokinetics? Biochemistry, molecular biology, physical chemistry, mathematics, enzymology, membrane transport, analytical chemistry, regenerative medicine, computer science, and so on. The 38th Annual Meeting of the Japanese Society for Pharmacokinetics and Pharmacodynamics (JSPS) / The 23rd International Joint Meeting of the Cytochrome P450 International Conference, to be held in September this year, is planned with attractive lectures and symposia under the theme “Discovering New Knowledge and Skills in Life Science and Drug Discovery: Learning from the Past, Understanding the Future. I am going to discover new science in syn- and pharmacokinetics at this convention. (M.T.)

Topics

Interview with the President: Highlights of the ICCP450/JSSX International Joint Congress in Shizuoka, 2023

Koichi Yoshinari, Department of Hygiene and Molecular Toxicology, Faculty of Pharmaceutical Sciences, University of Shizuoka
Shingo Nagano, Department of Chemical and Bio-Applications Engineering, Graduate School of Engineering, Tottori University

　The 38th Annual Meeting of the Japanese Society of Pharmacokinetics (JSSX), the international joint meeting with the 23rd International Cytochrome P450 Conference. We interviewed Dr. Yoshinari and Dr. Nagano about the appeal points of the joint meeting and summarized them in this video. We hope you will understand the outline of the annual meeting and feel the enthusiasm of the meeting chairpersons. (For the video, please visit the NL homepage )

NEW POWER for pharmacokinetic research

Pharmacokinetic Research in Clinical Practice

Takaaki Yamada, Laboratory of Medical Pharmaceutics, Faculty of Pharmacy, Wakayama Medical University

　My name is Takaaki Yamada, and I have been given the opportunity to contribute to the newsletter of the Japanese Society of Pharmacokinetics and Pharmacodynamics. I would like to express my sincere gratitude to the members of the editorial board for giving me this precious opportunity. I have been working as a hospital pharmacist for 17 years in the Department of Pharmacy, Kyushu University Hospital after completing the master’s course at Nagasaki University Graduate School of Pharmaceutical Sciences. I would like to take this opportunity to introduce the pharmacokinetic research I have been engaged in and my future goals, including my personal history and experiences. … ( To be continued on NL website / Members Only )

Introduction to Pharmacokinetic Studies in Research and Development of Cell Therapy Products

Part 5: Modeling & Simulation (M&S) of Cell Therapy Products; How to perform M&S and human prediction of proliferating drug CAR-T cells?

Research Pharmacokinetics Laboratory, Takeda Pharmaceutical Company Limited
Akihiko Goto, Shunsuke Yamamoto, Miyu Nakayama, Yu Moriya

　Hello! This is the last in the series of “Introduction to Pharmacokinetics in R&D of Cell Therapy Drugs”. In this series, we have introduced an overview of analytical methods, pitfalls to watch out for, and examples of cellular pharmacokinetics (CK) and biodistribution (BD). In this final installment, we would like to introduce model analysis using CK/BD data generated by the analytical methods we have introduced so far. Almost all of the examples of model analysis of cell therapy products are immune cells such as chimeric antigen receptor T cells (CAR-T cells), so this part also introduces examples of CAR-T cells. … ( To be continued at NL website / Members Only )

Technology and Research Materials (Company Advertisement)

Simple and Sensitive Quantification Solution for Cyclic Peptides

AB SCIEX Co.

　Cyclic peptides have a complex tertiary structure, making high baseline interference and fragmentation by collision-induced dissociation (CID) difficult, making sensitive quantitation difficult. In this technical note, we evaluate a workflow for the sensitive determination of cyclic peptide Eptifibatide in rat plasma using the ZenoTOF7600 system in the Zeno SIM, Zeno CID, and Zeno EAD (Electron Activated Dissociation) modes. The results of this study are presented in the following table. … ( visit the NL website for more information )